HEALTH.2010.2.4.4-1
HEALTH.2010.2.4.4-1
6 projects · €31,278,516 total EU contribution (project-level) · 49 participating organizations · 15 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€31,278,516
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (8)
- Spain (8)
- UK (6)
- DK (5)
- France (5)
- Italy (3)
- SE (3)
- Netherlands (2)
- PL (2)
- AT (1)
- BE (1)
- CZ (1)
- IE (1)
- LT (1)
- NO (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM2 projects · FR
- KU Leuven2 projects · BE
- KING'S COLLEGE LONDON2 projects · UK
- REGIONH2 projects · DK
- RS2 projects · SE
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 projects · NL
- ALMAC1 projects · UK
- AMT1 projects · NL
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 projects · FR
- GENETHON1 projects · FR
- BioNTech IMFS1 projects · DE
- CAU1 projects · DE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196 PADDINGTON · 261358 | FP7 | €5,816,314 | €8,589,885 | Details |
Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation MABSOT · 261468 | FP7 | €5,929,064 | €7,844,900 | Details |
Clinical development of Enzyme Replacement Therapy in alpha-Mannosidosis patients using recombinant human enzyme ALPHA-MAN · 261331 | FP7 | €5,887,150 | €8,028,469 | Details |
Immunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatment IMPACTT · 261095 | FP7 | €5,376,180 | €7,055,167 | Details |
Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector GENEGRAFT · 261392 | FP7 | €4,961,654 | €6,584,623 | Details |
Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria AIPGENE · 261506 | FP7 | €3,308,154 | €4,347,949 | Details |